Dementia with Lewy Bodies vs Alzheimer's Disease: sAPPα (CSF)


Back to the Top

sAPPα is a secreted peptide produced from APP processing along the "non-amyloidogenic" pathway. Meta-analysis did not show a difference in the levels of sAPPα in the cerebrospinal fluid of  people with dementia with Lewy bodies compared with people with Alzheimer's disease. However, a paucity of data limited the meta-analysis, with only two eligible studies. For comparison, levels of sAPPα in cerebrospinal fluid are similar in control subjects and people with Alzheimer's disease.

Loading data...

How to interpret a forest plot: Each individual effect size (ES) is a ratio of the mean biomarker level in one condition over the mean level in another condition. An ES equal to 1 means that the two conditions had identical mean values. An ES > 1 indicates higher levels in the first condition, whereas an ES < 1 indicates lower levels in the first condition. The overall ES, indicated by a black diamond, is a weighted average of the individual effect sizes. The weight of each data point was determined by the inverse of the variance and is reflected in the size of each square. The width of the overall ES diamond is determined by the 95 percent confidence interval. Data out of range of the scale, including ES and confidence intervals, are indicated by an arrowhead at the edge of the plot, when applicable. 

Version 3.0, July 2021.